Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
- 173 Downloads
Pharmacokinetics, absorption, metabolism, and excretion of ivosidenib, a mutant isocitrate dehydrogenase-1 inhibitor, were determined in healthy male subjects.
In this open-label phase I study, a single dose of [14C]ivosidenib (500 mg, 200 µCi/subject) was orally administered to eight subjects (CYP2D6 extensive, intermediate, or poor metabolizers) under fasted conditions. Blood, plasma, urine, and fecal samples were assayed for radioactivity and profiled for metabolites. Ivosidenib plasma concentrations were determined using LC–MS/MS. Metabolites were separated using reverse-phase HPLC and analyzed using high-resolution LC–MS and LC–MS/MS.
Ivosidenib was readily absorbed and slowly eliminated from plasma. Median Tmax of both unchanged ivosidenib and radioactivity in plasma was 4 h. Plasma t½ values for total radioactivity and ivosidenib were 71.7 and 53.4 h, respectively. The mean AUC0–72 blood-to-plasma total radioactivity concentration ratio was 0.565, indicating minimal partitioning to red blood cells. CYP2D6 genotype had no effect on ivosidenib exposure. The mean recovery of radioactivity in excreta was 94.3% over 360 h post-dose; the majority was excreted in feces (77.4 ± 9.62%) with a low percentage recovered in urine (16.9 ± 5.62%), suggesting fecal excretion is the primary route of elimination. Unchanged [14C]ivosidenib accounted for 67.4% of the administered radioactivity in feces. Only [14C]ivosidenib was detected in plasma, representing 92.4% of the total plasma radioactivity. Thirteen metabolites were structurally identified in excreta.
Ivosidenib was well-absorbed, slowly metabolized to multiple oxidative metabolites, and eliminated by fecal excretion, with no CYP2D6 effect observed. Unchanged ivosidenib was the only circulating species in plasma.
KeywordsAbsorption Metabolism Excretion Isocitrate dehydrogenase-1 (IDH1) Ivosidenib (AG-120) Metabolites LC–MS/MS Cytochrome P450
The authors would like to acknowledge the contributions of Covance Clinical for conducting the study and Covance Drug Metabolism and Pharmacokinetics Department for ADME profiling. We would like to also thank Gary Conner, Camelia Gliser, Shijie Zhang, and Huayu Xiong (Agios) for their help in conducting the study; and Christine Ingleby Ph.D. (of Excel Medical Affairs, Horsham, UK, funded by Agios) and Allyson Bower (Agios) for editorial assistance with the manuscript. We would also like to thank the volunteers who participated in the study.
All authors performed data analysis and interpretation, as well as manuscript writing, review, and approval.
This study was supported financially by Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
Compliance with ethical standards
Conflict of interest
All authors were paid employees of Agios Pharmaceuticals, Inc., Cambridge, MA, USA at the time of the study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Dang L, Su SM (2017) Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem 86:305–331. https://doi.org/10.1146/annurev-biochem-061516-044732 CrossRefPubMedGoogle Scholar
- 3.Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744. https://doi.org/10.1038/nature08617 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234. https://doi.org/10.1016/j.ccr.2010.01.020 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344. https://doi.org/10.1084/jem.20092506 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–469. https://doi.org/10.1038/embor.2011.43 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478. https://doi.org/10.1038/nature10860 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30. https://doi.org/10.1016/j.ccr.2010.12.014 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567. https://doi.org/10.1016/j.ccr.2010.11.015 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K (2018) Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9:300–305. https://doi.org/10.1021/acsmedchemlett.7b00421 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630. https://doi.org/10.1126/science.1236062 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378:2386–2398. https://doi.org/10.1056/NEJMoa1716984 CrossRefGoogle Scholar
- 13.Mellinghoff IK, Touat M, Maher E, de la Fuente M, Cloughesy TF, Holdhoff M, Cote GM, Burris H, Janku F, Huang R, Young RJ, Ellingson B, Nimkar T, Jiang L, Ishii Y, Choe S, Fan B, Steelman L, Yen K, Bowden C, Pandya S, Wen PY (2017) AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: updated results from the phase 1 non-enhancing glioma population. Neuro Oncol 19(suppl 6):ACTR–A46. https://doi.org/10.1093/neuonc/nox168.037 CrossRefGoogle Scholar
- 14.Lowery MA, Abou-Alfa GK, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Ishii Y, Auer J, Gliser C, Agresta SV, Pandya SS, Zhu AX (2017) Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 35(suppl):A4015. https://doi.org/10.1200/JCO.2017.35.15_suppl.4015 CrossRefGoogle Scholar
- 15.US Food and Drug Administration (2018) FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm. Accessed 1 Nov 2018
- 16.Dai D, DiNardo C, Stein E, de Botton S, Attar E, Liu H, Liu G, Lemieux I, Agresta S, Yang H, Fan B (2018) Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study. J Clin Oncol 36(15):Abstr2581. https://doi.org/10.1200/JCO.2018.36.15_suppl.2581 CrossRefGoogle Scholar
- 17.Dai D, Yang H, Nabhan S, Hickman D, Liu G, Zacher J, Vutikullird A, Prakash C, Agresta S, Bowden C, Fan B (2019) Effect of itraconazole, food and ethnic origin on pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol (Under revision)Google Scholar